Friday, February 24, 2017 5:04:45 AM
Knowing second-line anti-PD-1 non-responder treatments for advanced melanoma are reserved primarily for Yervoy (around 10% ORR in anti-PD-1 non-responder population), you can either go the route of combining Keytruda with Yervoy and get on the order of 50% grade 3-4 AEs, 35% dropouts, and 20% best overall responses, or you put a patient on an ImmunoPulse IL-12/keytruda combination that observes less than 5% grade 3-4 AEs, 0% dropouts, and thus far achieves 30% responses (including complete response).
Merck needs a therapy in the anti-PD-1 non-responder setting for advanced melanoma - they don't have an anti-ctla-4 checkpoint inhibitor like BMY's Yervoy. This is clearly an untapped market for Merck.
Don't ask me why the market reacted the way it did to the data announcement - these aren't treatment naive first-line patients. Existing therapies in the anti-PD-1 non-responder second line setting for advanced melanoma are clearly more toxic and less effective.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM